Preparation and use of therapeutic antibodies primarily of human origin

Biologicals

Volumn 36, Issue 6, 2008, Pages 363-374

  Stiehm, E Richard ^a   Keller, Margaret A ^b   Vyas, Girish N ^c  

^a UCLA MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody therapy; Immunoglobulin intravenous; Immunoglobulin subcutaneous; Immunoglobulins; Passive prophylaxis

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; BOTULINUM ANTISERUM; CETUXIMAB; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIPHTHERIA ANTIBODY; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; INFLIXIMAB; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RANIBIZUMAB; RHESUS D ANTIBODY; RITUXIMAB; TETANUS ANTIBODY; TETANUS TOXOID; THYMOCYTE ANTIBODY; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VACCINIA ANTIBODY; VARICELLA ZOSTER VACCINE;

ABSCESS; ACIDOSIS; ACUTE GRANULOCYTIC LEUKEMIA; AGAMMAGLOBULINEMIA; ALLERGIC DISEASE; ANTIBODY PRODUCTION; ARTHRALGIA; ASEPTIC MENINGITIS; ATAXIA TELANGIECTASIA; B CELL LYMPHOMA; BLOOD VISCOSITY; BOTULISM; BREAST CANCER; BURN; CHICKENPOX; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; DRUG INHIBITION; DRUG OVERDOSE; ENCEPHALITIS; ENTERITIS; FIBROSIS; GRAFT REJECTION; HEADACHE; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; KIDNEY FAILURE; MEASLES; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NERVE INJURY; NEUTROPENIA; PASSIVE IMMUNIZATION; POLYMYOSITIS; PREMATURITY; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; PSORIASIS; RABIES; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SHORT LIMBED DWARFISM; SIDE EFFECT; SMALLPOX; SNAKEBITE; STROKE; TETANUS; THROMBOSIS; TRANSIENT HYPOGAMMAGLOBULINEMIA OF INFANCY; TRANSIENT ISCHEMIC ATTACK; VACCINIA; VEIN THROMBOSIS; VIRUS INFECTION; VIRUS TRANSMISSION; WISKOTT ALDRICH SYNDROME;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; DRUG DESIGN; HUMANS; IMMUNE SERA; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MODELS, THEORETICAL;

ANIMALIA;

EID: 56949102212     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2008.07.002     Document Type: Review

References (79)

1. Farrugia A. International movement of plasma and plasma contracting. Dev Biol (Basel) 120 (2005) 85-96
2. Burnouf T. Modern plasma fractionation. Transfus Med Rev 21 (2007) 101-117
3. Parkkinen J., Rahola A., von Bonsdorff L., Tölö H., and Törmä E. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 90 (2006) 97-104
4. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
5. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 355 (2000) 735-740
6. Hale G. Therapeutic antibodies - delivering the promise?. Adv Drug Deliv Rev 58 (2006) 633-639
7. Johnston S.L. Biologic therapies: what and when?. J Clin Pathol 60 (2007) 8-17
8. Lee C.M., Iorno N., Sierro F., and Christ D. Selection of human antibody fragments by phage display. Nat Protoc 2 (2007) 3001-3008
9. Winter G., Griffiths A.D., Hawkins R.E., and Hoogenboom R.H. Making antibodies by phage display technology. Annu Rev Immunol 12 (1994) 433-455
10. Suomela H. Inactivation of viruses in blood and plasma products. Transfus Med Rev 7 (1993) 42-57
11. Vyas G.N., Yang G., and Murphy E.L. Transfusion-related transmissible diseases: detection by polymerase chain reaction-amplified genes of the microbial agents. Transfus Med Rev 8 (1994) 253-266
12. Willkommen H., Schmidt I., and Lower J. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals 27 (1999) 325-331
13. Lever A.M., Webster A.D., Brown D., and Thomas H.C. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 2 (1984) 1062-1064
14. Ochs H.D., Fischer S.H., and Virant F.S. Non-A non-B hepatitis and intravenous immunoglobulin. Lancet 1 (1985) 404-405
15. Bjorkander J., Cunningham-Rundles C., Lundin P., Olsson R., Söderström R., and Hanson L.A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 84 (1988) 107-111
16. Bjoro K., Frøland S.S., Yun Z., Sandal H.H., and Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331 (1994) 1607-1611
17. Lehner P.S., and Webster A.D. Hepatitis C from immunoglobin infusions. BMJ 306 (1993) 1541-1542
18. Williams P.E., Yap P.L., Gillon J., Crawford R.J., Urbaniak S.J., and Galea G. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang 57 (1989) 15-18
19. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 43:505-509, 1994.
20. Schiff R.I. Transmission of viral infections through intravenous immune globulin. N Engl J Med 331 (1994) 1649-1650
21. Grady G.F., and Vyas G.N. Blood-transmitted prions and variant Creutzfeldt-Jakob disease. Biologicals 35 (2007) 75-77
22. Hypogammaglobulinaemia in the United Kingdom. Summary report of a Medical Research Council working-party. Lancet i (1969) 163-168
23. Stiehm E.R. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 16 (1997) 696-707
24. Ellis E.F., and Henney C.S. Adverse reactions following administration of human gamma globulin. J Allergy 43 (1969) 45-54
25. Vyas G.N., Perkins H.A., and Fudenberg H.H. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 2 (1968) 312-315
26. Amer J., Ott E., Ibbott F.A., O'Brien D., and Kempe C.H. The effect of monthly gamma-globulin administration on morbidity and mortality from infection in premature infants during the first year of life. Pediatrics 32 (1963) 4-9
27. Siber G.R., Werner B.G., Halsey N.A., Reid R., Almeido-Hill J., Garrett S.C., et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 122 (1993) 204-211
28. Matheson D.S., Clarkson T.W., and Gelfand E.W. Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin. J Pediatr 97 (1980) 153-155
29. Buckley R.H., and Schiff R.I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325 (1991) 110-117
30. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 100 (1997) 151-157
31. Dwyer J.M. Manipulating the immune system with immune globulin. N Engl J Med 326 (1992) 107-116
32. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15 (2004) 3256-3262
33. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 (2006) 459-466
34. Nimmerjahn F., and Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26 (2008) 513-533
35. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., and Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376
36. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 (2008) 1109-1117
37. Ammann A.J., Ashman R.F., Buckley R.H., Hardie W.R., Krantmann H.J., Nelson J., et al. Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 22 (1982) 60-67
38. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553
39. Apfelzweig R., Piszkiewicz D., and Hooper J.A. Immunoglobulin A concentrations in commercial immune globulins. J Clin Immunol 7 (1987) 46-50
40. Skvaril F., and Gardi A. Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis J 7 (1988) S43-S48
41. Fischer G.W., Cieslak T.J., Wilson S.R., Weisman L.E., and Hemming V.G. Opsonic antibodies to Staphylococcus epidermidis: in vitro and in vivo studies using human intravenous immune globulin. J Infect Dis 169 (1994) 324-329
42. Cunningham-Rundles C., Bjorkander J., and Hanson L.A. Therapeutic use of an IgA-depleted intravenous immunoglobulin product. In: Morell A., and Nydeggers U.E. (Eds). Clinical use of intravenous immunoglobulins (1986), Academic Press, New York 87-96
43. Ashida E.R., and Saxon A. Home intravenous immunoglobulin therapy by self-administration. J Clin Immunol 6 (1986) 306-309
44. Kobayashi R.H., Kobayashi A.D., Lee N., Fischer S., and Ochs H.D. Home self-administration of intravenous immunoglobulin therapy in children. Pediatrics 85 (1990) 705-709
45. Sorensen R.U., Kallick M.D., and Berger M. Home treatment of antibody-deficiency syndromes with intravenous immune globulin. J Allergy Clin Immunol 80 (1987) 810-815
46. Schiff R.I., Sedlak D., and Buckley R.H. Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency. J Allergy Clin Immunol 88 (1991) 61-67
47. Rosenfeld E.A., Shulman S.T., Corydon K.E., Mason W., Takahashi M., and Kuroda C. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 126 (1995) 1000-1003
48. Duhem C., Dicato M.A., and Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 97 Suppl 1 (1994) 79-83
49. Stiehm E.R. Immune globulin therapy. In: Mintzs P.D. (Ed). Transfusion therapy: clinical principles and practice (2005), AABB Press, Bethesda, MD 391-422
50. Stiehm E.R. Recent progress in the use of intravenous immunoglobulin. Curr Probl Pediatr 22 (1992) 335-348
51. Burks A.W., Sampson H.A., and Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314 (1986) 560-564
52. Kato E., Shindo S., Eto Y., Hashimoto N., Yamamoto M., Sakata Y., and Hiyoshi Y. Administration of immune globulin associated with aseptic meningitis. JAMA 259 (1988) 3269-3271
53. Vera-Ramirez M., Charlet M., and Parry G.J. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 42 (1992) 1636-1637
54. Sekul E.A., Cupler E.J., and Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121 (1994) 259-262
55. Stiehm E.R., Casillas A.M., Finkelstein J.Z., Gallagher K.T., Groncy P.M., Kobayashi R.H., et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 101 (1998) 848-849
56. Brox A.G., Cournoyer D., Sternbach M., and Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 82 (1987) 633-635
57. American Academy of Pediatrics. Active and passive immunization. In: Pickering L.K. (Ed). Red Book: Report of the Committee on Infectious Diseases (2006), American Academy of Pediatrics, Elk Grove Village, IL 36-37
58. Sacher R.A. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108 (2001) S139-S146
59. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
60. Kainulainen L., Varpula M., Liippo K., Svedström E., Nikoskelainen J., and Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 104 (1999) 1031-1036
61. Bjorkander J., Bengtsson U., Oxelius V.A., and Hanson L.A. Symptoms in patients with lowered levels of IgG subclasses, with or without IgA deficiency, and effects of immunoglobulin prophylaxis. Monogr Allergy 20 (1986) 157-163
62. Knutsen A.P. Patients with IgG subclass and/or selective antibody deficiency to polysaccharide antigens: initiation of a controlled clinical trial of intravenous immune globulin. J Allergy Clin Immunol 84 (1989) 640-645 (discussion 645-7)
63. Silk H.J., Ambrosino D., and Geha R.S. Effect of intravenous gammaglobulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Hemophilus influenzae type b capsular polysaccharide antigen. Ann Allergy 64 (1990) 21-25
64. McKinney Jr. R.E., Katz S.L., and Wilfert C.M. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 9 (1987) 334-356
65. Mease P.J., Ochs H.D., and Wedgwood R.J. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med 304 (1981) 1278-1281
66. Crennan J.M., Van Scoy R.E., McKenna C.H., and Smith T.F. Echovirus polymyositis in patients with hypogammaglobulinemia. Failure of high-dose intravenous gammaglobulin therapy and review of the literature. Am J Med 81 (1986) 35-42
67. Abrahamsen T.G., Sandersen H., and Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 98 (1996) 1127-1131
68. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112 (2004) 1-7
69. Berger M., Cupps T.R., and Fauci A.S. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93 (1980) 55-56
70. Gardulf A., Hammarstrom L., and Smith C.I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338 (1991) 162-166
71. Ochs H.D., Gupta S., Kiessling P., Nicolay U., and Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26 (2006) 265-273
72. Gustafson R., Gardulf A., Granert C., Hansen S., and Hammerström L. Prophylactic therapy for selective IgA deficiency. Lancet 350 (1997) 865
73. Berger M., Cupps T.R., and Fauci A.S. High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy. JAMA 247 (1982) 2824-2825
74. Keller M.A., and Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13 (2000) 602-614
75. Stiehm E.R., and Keller M.A. Passive immunization. In: Feigin R.D. (Ed). Textbook of pediatric infectious diseases (2004), Saunders, Philadelphia, PA 3182-3220
76. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 6 (2006) 343-357
77. Liossis S.N., and Tsokos G.C. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 116 (2005) 721-729 quiz 7300
78. Presta L.G. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 116 (2005) 731-736 quiz 737
79. Sorenson R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm 13 (2007) 278-282